期刊文献+

LH-RH类似物在乳腺癌治疗中的应用 被引量:2

The application of LH-RH analogues in the treatment of breast cancer
下载PDF
导出
摘要 卵巢去势是绝经前乳腺癌的一种主要内分泌治疗方法 ,特别是药物性卵巢去势———促黄体生成素释放激素 (LH RH)类似物具有疗效好、停药后卵巢功能可恢复的特点 ,已取代手术和放疗成为治疗绝经前乳腺癌的一种主要治疗手段 ,现主要介绍LH RH类似物在乳腺癌治疗中的应用、药理学特点和研究进展。 Ovarian ablation is a main endocrine therapy in premenopausal breast cancer patients.The ovarian suppressing using luteinizing hormone-releasing hormone(LH-RH)anologues has the characteristic of efficacy and menstruation recovery after treatment.It has replaced surgery and radiotherapy as a main treatment approach in premenopausal breast cancer patients.LH-RH analogues application,pharmacy property and research development are being reported now.
出处 《癌症进展》 2005年第2期151-155,共5页 Oncology Progress
关键词 乳腺癌 LH-RH类似物 戈舍瑞林 breast cancer LH-RH analogues goserelin
  • 相关文献

参考文献17

  • 1[1]Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet, 1896, ii:104 被引量:1
  • 2[2]Nicholson RI, Walker KJ. Preclinical studies and antitumor mechanism of action of LHRH analogues. Cancer Treat Res,1988, 39:1 被引量:1
  • 3[3]Dixon AK, Robertson JFR, Jackson L, et al. Goserelin (Zoladex) in premenopausal advanced breast cancer: Duration of response and survival. Br J Cancer, 1990, 62:868 被引量:1
  • 4[4]Taylor CW; Green S Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer:An intergroup study. J Clin Oncol, 1998, 16 (3) : 994 被引量:1
  • 5[5]Jonat W, Kaufmann M, Blamey RW, et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserel in with or without tamoxifen in pre-and perimenopausal patients with advanced breast cancer.EurJ Cancer, 1995, 31 (A) :137 被引量:1
  • 6[6]Klijn JG, Blamey RW, Boccardo F, et al. Comibined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol,2001, 19 (2) :343 被引量:1
  • 7[7]Del Mastro L, Costantini M, Bianco AR. Adjuvant chemotherapy in breast cancer, N Engl J Med, 1995, 333 (9) :596 被引量:1
  • 8[8]Aebi S, Gelber S, Castiglione Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer. Lancet, 1996, 348 (9036) :1189 被引量:1
  • 9[9]Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Ccncer Research Association Study. J Clin Oncol, 2002, 20 (24) :4628 被引量:1
  • 10[10]Kaufmann M, Jonat W, Blamey R, et al. Survival analyses from the ZEBRA study: Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur-JCancer, 2003, 39 (12) :1711 被引量:1

同被引文献25

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部